Astellas Pharma Korea is continuing complex calculations for health insurance reimbursement listing of its metastatic urothelial cell carcinoma drug Padcev (enfortumab vedotin) in Korea.

The reimbursement is being discussed for the second-line monotherapy indication, which was first approved. However, as the company is seeking reimbursement for the potentially high-impact Keytruda+Padcev combination therapy, more factors remain in need of consideration.

According to industry sources, Astellas Pharma Korea is planning to file a reimbursement application for the Keytruda+Padcev combination therapy as a first-line treatment for urothelial cancer later this year.

The cl